GT Biopharma Doses First Patient in B7-H3 Phase I Trial, $9M Cash Runway
GT Biopharma dosed the first patient in its Phase I dose-escalation trial of GTB-5550, a B7-H3-targeted NK cell engager, on May 14, 2026. The company reported a $9 million cash balance as of March 31, 2026, funding operations through Q4 2026 with Phase I updates due in 2H 2026.
1. Patient Dosing Milestone
On May 14, 2026, GT Biopharma dosed the first patient in its Phase I dose-escalation basket trial of GTB-5550, marking the entry of its third TriKE candidate into clinical testing and the first to employ subcutaneous administration for enhanced patient convenience.
2. Trial Design and Indications
The IND for GTB-5550 cleared FDA review in February 2026, and the open-label trial prioritizes advanced prostate, ovarian and pancreatic cancer cohorts, focusing on patients with B7-H3–expressing solid tumors who have failed prior therapies.
3. Financial Runway and Catalysts
With approximately $9 million in cash as of March 31, 2026, the company anticipates funding operations through Q4 2026, setting the stage for anticipated Phase I readouts in the second half of the year as the dose escalation progresses.